Valuation : Protalix BioTherapeutics, Inc.

Market Cap 20Cr 17Cr 16Cr 15Cr 28Cr 1.91TCr 28Cr 190.5Cr 74Cr 961.47Cr 75Cr 73Cr 3.18TCr P/E 2026 *
13.1x
P/E 2027 * 45.1x
Enterprise Value 20Cr 17Cr 16Cr 15Cr 28Cr 1.91TCr 28Cr 190.5Cr 74Cr 961.47Cr 75Cr 73Cr 3.18TCr EV / Sales 2026 *
2.5x
EV / Sales 2027 * 2.93x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day+3.63%
1 week+7.35%
Current month+7.81%
1 month+6.46%
3 months+20.52%
6 months-11.28%
Current year+41.94%
1 week 2.34
Extreme 2.34
2.59
1 month 2.17
Extreme 2.17
2.7
Current year 1.72
Extreme 1.72
3.19
1 year 1.52
Extreme 1.5201
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 83 01/11/2014
Director/Board Member 59 30/06/2019
Date Insider Type Main position Quantity % Market Cap.
19/12/25 Buy

Chief Executive Officer

56,000 0.0696%
18/11/25 Sell

Director

168 0.0002%
03/09/25 Free

Chief Operating Officer

75,000 0.0941%
Change 5-day change 1-year change 3-year change Capi.($)
+4.44%+7.35%+59.69%+31.70% 20Cr
-0.22%-4.85%+61.27%+113.75% 1,06000Cr
-1.21%-0.83%+49.99%+61.40% 65TCr
-1.39%-1.28%+24.24%+75.33% 46TCr
-1.29%-2.42%+38.16%+40.00% 37TCr
-1.81%-1.33%+22.24%+37.81% 30TCr
-0.78%+0.41%+1.92%+12.00% 26TCr
-0.02%+1.20%+52.42%+71.09% 24TCr
-3.27%-0.68%-17.54%-54.50% 21TCr
+0.35%+2.93%+29.60%+91.64% 18TCr
Average -0.61%-0.34%+32.20%+48.02% 37.31TCr
Weighted average by Cap. -0.91%-2.15%+38.62%+66.18%

Financials

2026 *2027 *
Net sales 7.98Cr 6.85Cr 6.43Cr 5.87Cr 11Cr 761.08Cr 11Cr 76Cr 29Cr 383.96Cr 30Cr 29Cr 1.27TCr 6.82Cr 5.85Cr 5.49Cr 5.02Cr 9.47Cr 650.43Cr 9.52Cr 65Cr 25Cr 328.13Cr 26Cr 25Cr 1.09TCr
Net income 1.54Cr 1.32Cr 1.24Cr 1.13Cr 2.13Cr 146.64Cr 2.15Cr 15Cr 5.68Cr 74Cr 5.77Cr 5.65Cr 245.03Cr 44.63L 38.31L 35.95L 32.84L 61.97L 43Cr 62.27L 4.25Cr 1.65Cr 21Cr 1.68Cr 1.64Cr 71Cr
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
27/26/27 $2.560 +3.23% 2,80,526
26/26/26 $2.480 +3.33% 10,23,782
25/26/25 $2.400 -0.41% 4,97,742
24/26/24 $2.410 +1.26% 4,09,933
21/26/21 $2.380 0.00% 6,48,550
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.480USD
Average target price
11.00USD
Spread / Average Target
+343.55%

Quarterly revenue - Rate of surprise